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Abstract
 
A major challenge of AIDS research is the development of therapeutic vaccine strategies capa-
ble of inducing the humoral and cellular arms of the immune responses against HIV-1. In this
work, we evaluated the capability of DCs pulsed with aldrithiol-2–inactivated HIV-1 in induc-
ing a protective antiviral human immune response in SCID mice reconstituted with human
PBL (hu-PBL-SCID mice). Immunization of hu-PBL-SCID mice with DCs generated after
exposure of monocytes to GM-CSF/IFN-
 
 
 
 (IFN-DCs) and pulsed with inactivated HIV-1 re-
sulted in a marked induction of human anti–HIV-1 antibodies, which was associated with the
detection of anti-HIV neutralizing activity in the serum. This vaccination schedule also pro-
moted the generation of a human CD8
 
 
 
 T cell response against HIV-1, as measured by IFN-
 
 
 
Elispot analysis. Notably, when the hu-PBL-SCID mice immunized with antigen-pulsed
IFN-DCs were infected with HIV-1, inhibition of virus infection was observed as compared
with control animals. These results suggest that IFN-DCs pulsed with inactivated HIV-1 can
represent a valuable approach of immune intervention in HIV-1–infected patients.
Key words: antigen presenting cell • vaccine • neutralizing antibodies • CD8
 
 
 
 T lymphocytes • 
AIDS
 
Introduction
 
The immunopathogenesis of HIV-1 infection involves
multiple interactions between the virus and cells of the
immune system, which progressively lead to immune dys-
functions and subsequently to AIDS (1). Even though the
recent advances in the development of antiretroviral treat-
ment have dramatically reduced mortality and morbidity of
HIV-1–infected patients, the achievement of a long-term
immune control of viral replication still remains a major
challenge of AIDS research. In fact, viral rebound generally
occurs upon discontinuation of highly active antiviral ther-
apy (HAART; references 2–5), which is unlikely to eradi-
cate HIV replication within a reasonable period of time. In
fact, it has been estimated that the clearance of the T cell
viral reservoir may take up to 60 yr of infection containment
with continuous HAART (2). Therefore, an increasing in-
terest is now focused on the efforts to develop therapeutic
vaccination strategies to be combined with HAART to
achieve a durable immune control of HIV replication.
The development of an effective therapeutic anti-HIV
vaccine requires not only the characterization of the relevant
virus antigens potentially important for achieving immune
protection but also the identification of potent adjuvants,
which are necessary for inducing suitable levels of neutral-
izing antibodies as well as for ensuring the generation of a
vigorous antiviral CD8
 
 
 
 T cell response. In recent years, a
special attention has been given to the use of DCs as po-
tentially ideal cellular adjuvants for the development of
therapeutic vaccines (6, 7).
DCs are professional antigen-presenting cells capable of
stimulating naive T cells for the initiation of a primary im-
mune response and of processing extracellular antigens for
presentation by MHC class I molecules (8). Although the
use of DCs as cellular adjuvants for the preparation of
therapeutic vaccines against some human malignancies has
become a frequent experimental approach on the basis of
promising results generated in animal tumor models (7),
DC-based vaccination strategies in patients with chronic
infectious diseases, such as hepatitis B and C or HIV-1 in-
fection, are still at a very early stage of development. In a
previous paper, we showed that aldrithiol-2 (AT-2)–inacti-
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vated HIV-pulsed DCs generated after a 3-d treatment of
monocytes with GM-CSF and IFN-
 
 
 
 were highly effec-
tive in inducing a primary immune response against HIV-1
in vitro as well as in SCID mice reconstituted with human
PBL (9). However, no information was available on the ca-
pability of this DC-based immunization to induce impor-
tant immune correlates of protection against HIV-1, such
as neutralizing antibodies and virus-specific CD8
 
 
 
 T cells.
Likewise, it was important to establish whether DC-based
vaccination of hu-PBL-SCID mice could result in the in
vivo control of HIV-1 replication after virus challenge.
In the present report, we demonstrate that immunization
of hu-PBL-SCID mice with HIV-1–pulsed DCs generated
after exposure of monocytes to GM-CSF/IFN-
 
 
 
 results in
a remarkable induction of both human anti–HIV-1 anti-
bodies and CD8
 
 
 
 T cells reactive against HIV-1. More-
over, we report that this DC-based vaccination protocol
induces inhibition of virus replication after HIV-1 chal-
lenge of hu-PBL-SCID mice.
 
Materials and Methods
 
Cell Separation and Culture.
 
Peripheral blood mononuclear
cells were obtained from heparinized blood of healthy donors by
Ficoll density gradient centrifugation (Seromed). Monocytes
were isolated by column magnetic immunoselection (MACS Cell
Isolation Kits; Miltenyi Biotec). Positively selected CD14
 
 
 
monocytes (
 
 
 
98% as assessed by flow cytometry) were plated at
the concentration of 2 
 
 
 
 10
 
6 
 
cells/ml in RPMI 1640 (GIBCO
BRL), supplemented with 10% LPS-free FCS, 500 U/ml GM-
CSF, and either 250 U/ml IL-4 (R&D Systems) or natural IFN-
 
 
 
(Alfaferone; AlfaWasserman) at the concentration of 10,000 U/ml,
and cultured for 3 d as described previously (9). Negatively se-
lected PBLs were used to reconstitute SCID mice.
 
hu-PBL-SCID Mouse Model.
 
CB17 scid/scid female mice
(Charles River Laboratories) were used at 4 wk of age and kept
under specific pathogen-free conditions. Hu-PBLs were obtained
from the peripheral blood of healthy donors. All donors were
screened for HIV-1 and hepatitis before donation. The hu-PBLs
were obtained as described previously (9). Three or four mice for
each group were injected i.p. with 30–40 
 
 
 
 10
 
6
 
 cells and resus-
pended in 0.5 ml RPMI 1640 medium.
 
Immunization and Challenge of hu-PBL-SCID Mice.
 
HIV-1
(SF-162 strain) was propagated in PBMCs from HIV-1–negative
donors and virus titers were determined on PHA-stimulated
PBMC blasts. To prepare the inactivated HIV-1 for immuniza-
tion experiments, different SF-162 HIV-1 stocks were inactivated
by treatment for 1 h at 37
 
 
 
C with 2,2
 
 
 
-dithiodipyridine (al-
drithiol-2 [AT-2]) as described previously (9). The virus was ul-
tracentrifugated to remove treatment agents and contaminants,
resuspended in RPMI 1640 medium, and frozen at 
 
 
 
80
 
 
 
C until
use. 3 d after reconstitution with autologous human PBLs, hu-
PBL-SCID mice were injected i.p. with 2.5 
 
 
 
 10
 
6
 
 autologous
DCs, pulsed for 2 h at 37
 
 
 
C with AT-2–inactivated HIV-1 (100
ng p24). Mice were further immunized with the inactivated vi-
rus-pulsed DCs on day 7 and subjected to a final vaccination
boost consisting of AT-2–inactivated HIV alone (100 ng p24) on
day 14. In some experiments, we also immunized the hu-PBL-
SCID mice by three weekly injections of free AT-2–inactivated
virions (100 ng p24). 1 wk later, mice were challenged i.p. with
10
 
3
 
 TCID
 
50
 
 of HIV-1 SF162 strain.
 
ELISA for Human Immunoglobulins.
 
Sera from control and
vaccinated hu-PBL-SCID mice were tested for antibodies to
HIV-1 using a commercial ELISA kit detecting IgG, IgM, and
IgA specific to a series of envelope and core HIV-1 peptides (Ab-
bott Murex HIV-1.2.O). An ELISA system was used to quantify
human immunoglobulins to the ELDKWAS HIV-1 gp41 epitope
in the sera of the chimeras by using anti–human total Igs (Cappel-
Cooper Biomedical). All ELISAs were performed in duplicate
and laboratory standards were included on each plate. Sera from
nonimmunized hu-PBL-SCID mice were used as negative con-
trols of all the ELISA determinations. Values represent mean ad-
sorbance of each individual serum tested in duplicate. The cutoff
value was calculated as mean adsorbance value of all the control
sera plus 0.100 O.D. Sera showing A
 
490
 
 values higher than this
threshold were considered positive for anti-HIV antibodies.
 
Western Blot.
 
Sera from hu-PBL-SCID mice immunized
with AT-2/HIV-1–pulsed DCs were assayed by a commercial
Western blot kit (HIV kit; Cambridge Biotech). In brief, indi-
vidual nitrocellulose strips were incubated overnight with differ-
ent mouse serum samples (diluted 1:20) or with human positive
or negative control sera (diluted 1:1,000; Cambridge Biotech).
Sera from nonimmunized hu-PBL-SCID mice were included as
experimental negative controls. Visualization of the human Igs
specifically bound to HIV-1 proteins was obtained by incu-
bation with substrate chromogen after the addition of biotin-
conjugated goat anti–human IgG and streptavidin-conjugated
horseradish peroxidase.
 
Neutralization Assay.
 
Sera were serially diluted in RPMI
1640 medium containing 15% FCS in 96-well plates (Costar) in
duplicate, and 100 TCID
 
50
 
 of HIV-1 SF162 strain in a volume of
50 
 
 
 
l was added to each dilution. After a 2-h incubation at 37
 
 
 
C,
2 
 
 
 
 10
 
5
 
 PHA-activated PBMCs were added to each well in the
presence of 50 U/ml IL-2. After 3 d, cells were washed three
times and 50 U/ml IL-2 (Roche Diagnostic) were added. Culture
supernatants were tested for p24 production after 7 d by a HIV-1
p24 ELISA commercial kit (NEN Life Science Products). Sera
from nonimmunized hu-PBL-SCID mice were used as negative
controls for neutralizing activity.
 
Cell Recovery from Peritoneal Cavity and Organs of the SCID
Mice.
 
hu-PBL-SCID mice were killed 7–10 d after viral chal-
lenge. Cells were collected from the peritoneal cavity and spleen.
Spleens were disrupted, connective tissue and debris were al-
lowed to settle, and the single cell suspensions were washed twice
in RPMI 1640 medium. Human cells from mouse spleens were
enriched by Ficoll density gradient centrifugation and used for
subsequent analyses.
 
Elispot Assay. 
 
Human cells recovered from either the spleen
or peritoneal lavages of hu-PBL-SCID mice of each group were
pooled (three or four mice per group). The presence of HIV-1–
reactive CD8
 
 
 
 T lymphocytes was tested using as stimulators/
targets autologous EBV-transformed B-lymphoblastoid cell lines
(BLCLs) or DCs, infected with either HIV-1 SF162 strain or re-
combinant vaccinia virus vectors encoding gag and pol antigens
from the IIIB strain of HIV-1. Stimulator/target cells were in-
fected with the HIV-I SF162 strain (MOI 
 
 
 
 0.1) or recombi-
nant HIV-1 vaccinia virus vectors (MOI 
 
 
 
 3) for 48 and 12 h,
respectively, washed, irradiated, and used as antigen-presenting
cells. Control uninfected BLCLs, vaccinia vector infected
BLCLs, or uninfected DCs were used as stimulators/targets for
the calculation of background spots to be subtracted for the
evaluation of the specific number of IFN-
 
 
 
–spot-forming cells.
PBMCs cultures treated with 1 
 
 
 
g/ml PHA served as positive
controls. The cells were added at 10
 
6
 
 per well and incubated atT
h
e
 
J
o
u
r
n
a
l
 
o
f
 
E
x
p
e
r
i
m
e
n
t
a
l
 
M
e
d
i
c
i
n
e
 
363
 
Lapenta et al. Brief Definitive Report
37
 
 
 
C overnight in a final volume of 2 ml of medium (RPMI
1640 supplemented with 2 mM 
 
l
 
-glutamine and 10% heat-inac-
tivated FCS).
After incubation with autologous BLCLs at a responder/stim-
ulator ratio of 4:1, CD8
 
 
 
 T cells were positively selected by
MACS Micro Beads (Miltenyi Biotec) and tested in an ELISPOT
assay for the production of IFN-
 
 
 
 (Euroclone Ltd.). In brief, 10
 
5
 
CD8
 
 
 
 T cells (100 
 
 
 
l /well) were dispensed in a 96-well anti–
IFN-
 
 
 
 antibody-coated plate; after overnight incubation and cell
lysis, trapped cytokine molecules were revealed by a secondary
biotinylated detection antibody and developed by incubating
with streptavidin–alkaline phosphatase, followed by incubation
with BCIP substrate in a gel overlay. Colored spots were enu-
merated on an inverted microscope at a magnification of 40.
Analysis of the CD8
 
 
 
 T cell response to the HLA-A
 
*
 
0201–
restricted CTL epitope SL9 (10, 11) was performed by pulsing
BLCL cells with 5 
 
 
 
 10
 
 
 
6
 
 M of the synthetic peptide SL9
(SLYNTVATL). 
 
Detection of HIV-1 Infection.
 
PCR detection of HIV-1 provi-
ral sequences. DNA was extracted from spleens and lymph nodes
of the hu-PBL-SCID mice. The presence of human sequences
was determined by DNA-PCR using specific primers for the
HLA-DQ
 
 
 
 gene, whereas HIV-1 proviral DNA was detected by
specific amplification of HIV-1 gag sequences as described previ-
ously (12). In each experiment, the sensitivity of the assay was
tested by amplifying serial dilutions of DNA prepared from 8E5
cells (which harbor one proviral copy per cell). 8E5 DNA was se-
rially diluted into SCID mouse cell DNA.
 
Co-cultivation Assay.
 
10
 
5
 
 cells from the peritoneal lavages
were cocultured with 10
 
5
 
 human allogeneic T cells, preventively
activated with 5 
 
 
 
g/ml PHA, and cultivated in the presence of 50
U/ml IL-2. Virus replication was determined after 10 d of culture
by detection of p24 gag antigen in culture supernatant using a
commercial ELISA kit (Dupont).
 
Results and Discussion
 
All the mice immunized with AT-2/HIV-1–pulsed
IFN-DCs exhibited a clear-cut antibody response to HIV-1,
as revealed by a commercial ELISA kit detecting IgG,
IgM, and IgA specific to a series of envelope and core pep-
tides (Fig. 1 A) as well as by Western blot analysis (Fig. 1
B), which revealed the presence of antibodies to virtually
all HIV proteins. A detectable, though even less intensive,
antibody response was also observed in sera from mice vac-
cinated with AT-2/HIV-1–pulsed IL-4–DCs (Fig. 1, A
and B). Notably, sera from immunized animals did not
show any reactivity against irrelevant antigens, such as re-
combinant HCV proteins, whereas very low and compara-
ble levels of human antibodies against tetanus toxoid were
detected in both control and immunized xenochimeras
(unpublished data), ruling out a nonspecific adjuvant or mi-
togenic effect by the HIV vaccine preparation. In contrast,
hu-PBL-SCID mice immunized with virus-pulsed IFN-
Figure 1. Characterization of
the antibody response against
HIV-1 in hu-PBL-SCID mice
immunized with DCs pulsed
with AT-2–inactivated HIV-1.
(A) Immune reactivity toward
HIV envelope and core proteins
in individual xenochimeric mice.
Undiluted sera from control and
vaccinated hu-PBL-SCID mice
were tested for antibodies to
HIV-1 using a commercial
ELISA kit detecting IgG, IgM,
and IgA specific to a series of en-
velope and core peptides (AB-
BOTT Murex HIV-1.2.O).
Each bar represents the anti-HIV
antibody reactivity in individual
mouse sera collected 7 d after
completion of the immunization
schedule. Cutoff value has been
calculated as recommended by
the manufacturer and has been
subtracted. (B) Western blot
characterization of the human
humoral response to viral anti-
gens in individual sera from im-
munized xenochimeric mice.
The assay was performed on
mouse sera collected 7 d after
completion of the immunization schedule as described in Materials and Methods. Sera from nonimmunized hu-PBL-SCID mice were included as exper-
imental negative control (CTR) together with both human positive ( ) and negative ( ) control sera. (C) ELISA detection of antibodies to the HIV-1
gp41 ectodomain epitope ELDKWAS in the sera from immunized hu-PBL-SCID. 10-fold dilutions of the sera from four mice in each experimental
group were tested. Each bar represents the mean   SE of values of four serum samples from individual mice. (D) HIV-neutralizing activity of sera from
immunized hu-PBL-SCID mice. Twofold serial dilutions of mouse sera were tested for inhibition of HIV infection of PHA-activated T cells in vitro as
described in Materials and Methods. Sera from nonimmunized hu-PBL-SCID were used as controls. The figure shows the results from one representative
experiment (four mice per group) out of five.T
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DCs exhibited high levels of antibodies reacting against the
gp41 ectodomain epitope ELDKWAS (Fig. 1 C), also rec-
ognized by the 2F5 mAb, which is known to exert cross-
neutralization of some divergent HIV-1 isolates (13). Of
interest, all the sera from mice immunized with virus-
pulsed IFN-DCs showed in vitro anti–HIV-1 neutralizing
activity at dilutions up to 1:64 (Fig. 1 D). A considerably
lower neutralizing activity was detected in the sera from
mice immunized with virus-pulsed IL-4–DCs, whereas
sera from control hu-PBL-SCID mice did not show any
activity, even at the 1:2 dilution (Fig. 1 D).
We evaluated whether the immunization of hu-PBL-
SCID mice with AT-2/HIV-pulsed DCs could result in
the generation of human anti-HIV CD8
 
 
 
 T cells, which
are considered as an important immune correlate of protec-
tion (14–16). As shown in Fig. 2 A, vaccination of hu-
PBL-SCID mice with virus-pulsed IFN-DCs resulted in a
clear-cut generation of HIV-1–specific CD8
 
 
 
 T cells. A
significant CD8
 
 
 
 T cell response against the gag and pol
proteins of HIV-1 was also observed in animals immunized
with AT-2/HIV-1–pulsed IL-4–DCs, even though the ex-
tent of the response was lower than that detected in mice
immunized with virus-pulsed IFN-DCs (Fig. 2 A). Of
note, no CD8 T response to HIV-1 was observed when
hu-PBL-SCID mice were immunized with free AT-2–
inactivated virus, which was also unable to induce detect-
able levels of specific antibodies against HIV-1 (Fig. 2 B).
In a subsequent experiment, we also evaluated the HLA-
A
 
*
 
0201–restricted response to the CTL epitope SL9
(SLYNTVATL) of the p17 HIV-1 gag protein using hu-
man cells recovered from either the spleen or the peritoneal
cavity of hu-PBL-SCID mice vaccinated with virus-pulsed
DCs. As illustrated in Fig. 2 C, vaccination of SCID mice
reconstituted with PBLs from an HLA-A
 
*
 
0201 individual
with virus-pulsed IFN-DCs elicited a strong CD8
 
 
 
 T cell
response toward the conserved SL9 epitope. A similar,
even though less pronounced, CD8
 
 
 
 T cell response di-
rected against the CTL epitope SL9 was also observed in
hu-PBL-SCID mice immunized with virus-pulsed IL-4–
DCs. Notably, in HIV-1–infected patients, this immu-
nodominant HIV-gag p17-derived epitope elicits strong
CTL response, which is maintained, even in the presence
of strong selective pressure to viral escape (10, 11).
In a second set of experiments, hu-PBL-SCID mice
were challenged i.p. with 10
 
3
 
 TCID
 
50
 
 of SF162 HIV-1 7 d
after a complete immunization schedule. 1 wk later, the
animals were assayed for the extent of viral infection/repli-
cation by measuring the proviral load in spleen and lymph
nodes as well as by testing the capability to rescue infec-
tious virus after coculture of cells recovered from the in-
Figure 2. Detection of HIV-
reactive human CD8  T cells in
immunized hu-PBL-SCID mice.
(A) Elispot analysis of anti–HIV-1
CD8  T cell response. Human
cells were recovered from three
spleens of hu-PBL-SCID mice
from each group and pooled.
The assay was performed using as
stimulators autologous BLCL
targets, infected with either
HIV-1 SF162 strain (BLCL  
HIV) or recombinant vaccinia
virus vectors encoding gag and
pol antigens from the IIIB HIV-1 strain (BLCL   Vv-gag-pol). Bars represent the CD8 
T cell response from hu-PBL-SCID mice immunized with virus-pulsed IFN-DCs or IL-4–
DCs, as compared with the basal CD8  T cell response in control nonimmunized xe-
nochimeric mice (CTR). The white bars in the first row represent the background values
after stimulation with uninfected BLCL targets for each experimental condition. The
panel shows the results of one representative experiment out of four. (B) Comparative
analysis of the anti–HIV-1 immune response after vaccination with either virus-pulsed
IFN-DCs (AT2/DC) or free inactivated HIV virions (AT2-HIV) as immunogen. The xe-
nochimeric mice were vaccinated and received two boost immunizations at 7-d intervals,
according to the immunization schedule described in Materials and Methods. Mice were
killed 7 d after the completion of the vaccination schedule. Elispot analysis of the anti–
HIV-1 CD8  T cell response. Human cells were recovered from three spleens hu-PBL-
SCID mice from each group and pooled. The assay was performed using as stimulators au-
tologous BLCL targets, infected with either HIV-1 SF162 strain (BLCL   HIV) or re-
combinant vaccinia virus vectors encoding gag and pol antigens from the IIIB HIV-1 strain (BLCL   Vv-gag-pol). Control uninfected BLCL were used
as stimulators/targets for the calculation of background spots for each experimental condition (white bars). Serum ELISA reactivity toward HIV envelope
and core proteins. Undiluted sera from control and vaccinated hu-PBL-SCID mice were tested for antibodies to HIV-1 using a commercial ELISA kit
detecting IgG, IgM, and IgA specific to a series of envelope and core peptides (ABBOTT Murex HIV-1.2.O). Mouse sera were collected 7 d after com-
pletion of the immunization schedule. Each bar represents the mean of the values of sera from three mice   SE for each experimental group. (C) Elispot
analysis of the HLA-A*0201–restricted CD8  T cell response to the CTL epitope “SL9” (SLYNTVATL) using human cells recovered from spleens and
peritoneal lavages (P.L.) of vaccinated xenochimeras. Elispot assay was performed after coculture of the human cells with peptide-pulsed target cells as de-
scribed in Materials and Methods. Bars represent the CD8  T cell response from hu-PBL-SCID mice immunized with virus-pulsed IFN-DCs or IL-4–
DCs, as compared with the basal CD8  T cell response in control nonimmunized xenochimeric mice (CTR). The white bars in the first row represent
the background values after stimulation with unpulsed BLCL targets for each experimental condition. The panel shows the results of one representative
experiment out of three.T
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fected mice with HIV-susceptible target cells. As shown in
Fig. 3, all the mice injected with unpulsed IFN-DCs
proved to be infected by HIV-1, as revealed by both PCR
analysis of DNA extracted from mouse tissues and coculti-
vation assay, similarly to the nontreated hu-PBL-SCID
mice. In contrast, only one out of the four mice immu-
nized with virus-pulsed IFN-DCs exhibited evidence of
infection by HIV-1 PCR analysis (Fig. 3 A) and no infec-
tious HIV could be rescued from the cells recovered from
any of these animals (Fig. 3 B). In a total set of four experi-
ments, in which hu-PBL-SCID mice were vaccinated with
virus-pulsed IFN-DCs, only 4 out of 16 mice proved to be
infected by HIV, whereas all the reconstituted and infected
control mice (16/16) showed signs of infection by HIV-1
PCR analysis of mouse tissues. Of interest, only the hu-
PBL-SCID mice vaccinated with AT-2/HIV–pulsed DCs
showed the presence of an anti-HIV CD8
 
 
 
 T cell response
(Fig. 3 C).
In the present work, we have provided the first in vivo
evidence on the efficacy of antigen-pulsed human DCs in
inducing an anti–HIV-1 protection, which is associated
with two main immune correlates, such as anti-HIV anti-
bodies and CD8
 
 
 
 T cells. Little information is available so
far on DC-mediated anti–HIV-1 immunity and only three
papers in virus-infected monkeys have provided some evi-
dence suggesting the advantage of using DCs for the devel-
opment of anti–HIV-1 vaccines (17–19). In our work, the
induction of an antibody response to HIV was invariantly
associated with the detection of HIV-neutralizing activity
of mouse sera. Even though neutralizing antibodies have
been shown to exert poor effects on the control of estab-
lished HIV-1 infection in vivo (20), they may contribute in
limiting virus cell-to-cell spread during the chronic infec-
tion phase. Notably, passive transfer of antibodies has been
shown to confer protection against HIV challenge in ani-
mal models (21, 22). However, such protection was ob-
tained with antibody concentrations higher than those
commonly achievable by vaccination.
In the present paper, we have also demonstrated the de-
velopment of an efficient HIV-1–specific CD8
 
 
 
 T cell re-
sponse in vaccinated hu-PBL-SCID mice. Several papers
have supported an important role of CD8
 
 
 
 T cells in the
control of HIV infection (14–16). CTL induction in HIV-
1–infected patients generally precedes the production of
any neutralizing antibody and has been considered instru-
mental in reducing viral load during primary infection (14).
Of note, an increase in CTL frequencies has been shown to
correlate with decline of viremia (16) and the importance
of CD8
 
 
 
 T cells has been well-documented by depletion
experiments in monkey models (15). Notably, the IFN-
DCs used in the present paper proved to be powerful cellu-
lar adjuvants for the generation of neutralizing antibodies
and CD8
 
 
 
 T cells against HIV-1, whereas the immature
monocyte-derived DCs generated in the presence of IL-4
Figure 3. Protection  from
HIV-1 challenge of hu-PBL-
SCID mice vaccinated with
IFN-DCs pulsed with AT-2–
inactivated HIV-1. hu-PBL-
SCID mice were challenged i.p.
with 103 TCID50 of SF162 HIV-1
7 d after a complete immuniza-
tion schedule with IFN-DCs
pulsed with AT-2–inactivated
HIV-1 as described in Materials
and Methods. A control group of
hu-PBL-SCID mice was neither
immunized nor challenged (non-
infected), whereas virus-infected
control groups were represented
by nonimmunized hu-PBL-SCID
mice (CTR) and mice injected
with unpulsed DCs. 1 wk after
HIV-1 infection, proviral load
was analyzed in spleen and
lymph nodes from infected hu-
PBL-SCID mice by PCR for
viral gag sequences (A). The sen-
sitivity of the assay was tested by
amplifying serial dilutions of
DNA prepared from 8E5 cells
that harbor one proviral copy/
cell (A). The presence of infectious HIV-1 was assessed by cocultivation of peritoneal cells rescued from individual mice with PHA-activated T lympho-
cytes and determination of the p24 protein in culture supernatants (B) as described in Materials and Methods. The human CD8  T cell response to HIV
antigens (C) was evaluated in cells pooled from the spleen or peritoneal lavages (P.L.) of four hu-PBL-SCID mice per group by IFN-  Elispot analysis as
described in Materials and Methods. Target/stimulator cells used in these experiments were autologous DCs. Bars represent the CD8  T cell response
from hu-PBL-SCID mice immunized with virus-pulsed IFN-DCs, as compared with the CD8  T cell response in control nonimmunized xenochimeric
mice (CTR) and to hu-PBL-SCID mice injected with unpulsed DCs. The white bars in the first row represent the background values after stimulation
with uninfected DC targets for each experimental condition. The figure shows the data from one representative experiment out of four. Four SCID mice
were included in each experimental group.T
h
e
 
J
o
u
r
n
a
l
 
o
f
 
E
x
p
e
r
i
m
e
n
t
a
l
 
M
e
d
i
c
i
n
e
 
366
 
Dendritic Cell–based Vaccination and Immune Protection Against HIV-1
 
showed a lower activity. The higher activity of IFN-DCs
could be explained by the strong Th-1 type of immune re-
sponse elicited by these cells (9) and is consistent with data
on the type I IFN-induced enhancement of antibody pro-
duction in mouse models (23, 24) as well as with recent
findings showing that human IFN-DCs induce a potent
CTL response against HLA-class I–restricted EBV antigens
(25). Thus, the use of highly active DCs, such as the IFN-
DCs, could explain, at least in part, the powerful immune
responses observed in our vaccination experiments in hu-
PBL-SCID mice. Second, the use of AT-2–inactivated
HIV-1 as immunogen for pulsing DCs may have repre-
sented an advantage for inducing a broad spectrum of im-
mune response with respect to the use of purified virus an-
tigens, as suggested by recent papers (26, 27).
In this report, the induction of the anti–HIV-1 immune
response was associated with a protection from HIV-1 in-
fection/replication when the animals were challenged with
the homologous SF-162 viral strain. Several other studies,
including the evaluation of the possible protection from the
infection with divergent HIV strains, need to be performed
in this practical animal model. In fact, the hu-PBL-SCID
mouse exhibits the unique characteristic of allowing the use
of human DCs for vaccination studies. However, one im-
portant limitation of the model is represented by the rapid
in vivo infection of human cells, which does not allow to
perform therapeutic immune interventions in chronic in-
fected animals under conditions closely mimicking the nat-
ural HIV-1 infection occurring in patients. Nevertheless,
the ensemble of the results presented here represent the first
“proof of concept” on the potential in vivo efficacy of hu-
man DC–based anti-HIV vaccines. Although our experi-
ments have been designed to evaluate the efficacy of DC-
based vaccines in a prophylactic context because of the
characteristics of the hu-PBL-SCID mouse model, the en-
semble of results may be more relevant to the design of
therapeutic vaccination strategies, as this potentially highly
effective vaccination strategy is not practicable for large
scale preventive immunization. We suggest that the com-
bined use of inactivated HIV-1 as immunogen and IFN-
DCs as cellular adjuvant can offer new perspectives for the
design of therapeutic vaccination strategies in HIV-1–
infected patients. IFN-DC–based therapeutic immuniza-
tion could be associated to HAART in the treatment of
acute HIV infection, to preserve both DCs and specific ac-
tivated CD4
 
 
 
 T lymphocytes taking advantage of a still-
intact CD4 repertoire. In the course of an established
chronic infection, IFN-DC–based immunization could be
beneficial for the persistence of CD8
 
 
 
 T cell response dur-
ing HAART, thus preventing specific CD8
 
 
 
 lymphocyte
reduction, which generally parallels viral load drop after an-
tiviral therapy.
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